AusCann (ASX:AC8) - CEO, Layton Mills
CEO, Layton Mills
Source: Layton Mills/LinkedIn
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • AusCann (AC8) has submitted its first module of DermaCann to the Australian Pesticides and Veterinary Medicines Association (APVMA) to support dogs with dermatological conditions
  • AusCann is aiming for its DermaCann product to become a world-first oral cannabinoid product for skin health in dogs
  • If approved, it would be the first APVMA medicine containing cannabinoids to be supplied via prescription through Australian veterinarians
  • The Australian submission complements the previous submission in South Africa and commercialisation plans in the US
  • Auscann is up 4.76 per cent, trading at 11 cents per share at 1:17 pm AEST

AusCann Group Holdings (AC8) has commenced its Australian product registration for DermaCann.

The company has submitted its first module to the Australian Pesticides and Veterinary Medicines Association (APVMA) to support dogs with dermatological conditions.

AusCann is aiming for its DermaCann product to become a world-first oral cannabinoid product for skin health in dogs. If approved, it would be the first APVMA medicine containing cannabinoids to be supplied via prescription through Australian veterinarians.

There are around one million dogs in Australia who suffer from dermatological conditions, and the global canine skin and dermatitis market is worth an estimated US$1.5 billion (about A$20 billion) globally.

The Australian submission complements the previous submission in South Africa and commercialisation plans in the US.

Last year, DermaCann was shown to be safe and effective at reducing inflammatory skin lesions in dogs diagnosed with atopic dermatitis.

CEO Layton Mills is looking forward to bringing this product to Australian vets.

“Commencing the formal registration pathway with APVMA is consistent
with AusCann’s objective of bringing safe, clinically developed and tested medicines for human and animal health to meet patients’ unmet health needs,” he said.

“We look forward to bringing this world-first product to veterinarians in Australia and other global markets.”

Auscann was up 4.76 per cent, trading at 11 cents per share at 1:17 pm AEST.

AC8 by the numbers
More From The Market Herald
Genetic Technologies (ASX:GTG) - CEO, Simon Morriss

" Genetic Technologies (ASX:GTG) expands EasyDNA into Indian and European markets

Genetic Technologies (ASX:GTG) has embarked on a significant expansion of its recently acquired at-home DNA testing…
The Market Herald Video

" PainChek (ASX:PCK) to receive govt funding for children’s disability app

PainChek (ASX:PCK) has been awarded a $392,820 grant from the Western Australia State Government's Future Health…
The Market Herald Video

" Prescient Therapeutics (ASX:PTX) granted key US patent for OmniCar platform

Prescient Therapeutics (ASX:PTX) has been granted a key US patent for its OmniCAR universal immune receptor…

" Antisense Therapeutics (ASX:ANP) dosing of muscular dystrophy drug on hold

Antisense Therapeutics (ASX:ANP) applies for partial clinical hold that limits dosing of its drug for muscular…